Vedolizumab
Treatment for Crohns Disease
Typical Dosage: 300 mg IV at weeks 0, 2, 6, then every 8 weeks
Effectiveness
70%
Safety Score
50%
Clinical Trials
95
Participants
6K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
300 mg IV at weeks 0, 2, 6, then every 8 weeks
Time to Effect
6-10 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30,000
Monitoring:$1,150
Side Effect Mgmt:$500
Total Annual:$31,650
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$150,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$70,333
Cost per Remission
$126,600
Active Clinical Trials
5 active trials recruiting for Vedolizumab in Crohns Disease
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706RECRUITINGPHASE4
304 participants
INTERVENTIONAL
Los Angeles, United States +72 more
Started: Aug 7, 2024
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320RECRUITINGPHASE3
120 participants
INTERVENTIONAL
Phoenix, United States +95 more
Started: Feb 10, 2022
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289RECRUITINGPHASE3
70 participants
INTERVENTIONAL
Garden Grove, United States +56 more
Started: Jan 22, 2025
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
NCT06581328RECRUITINGPHASE4
400 participants
INTERVENTIONAL
Birmingham, United States +77 more
Started: Mar 27, 2025
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
NCT06180382RECRUITINGPHASE4
220 participants
INTERVENTIONAL
Le Kremlin-Bicêtre, France +11 more
Started: Oct 31, 2024
Completed Clinical Trials
10 completed trials for Vedolizumab in Crohns Disease
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
NCT02038920COMPLETEDPHASE3
157 participants
INTERVENTIONAL
Nagoya, Japan +55 more
Started: Jan 28, 2014
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
NCT02425111COMPLETEDPHASE3
101 participants
INTERVENTIONAL
La Jolla, United States +78 more
Started: Mar 30, 2015
Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
NCT02630966COMPLETEDPHASE4
34 participants
INTERVENTIONAL
Nashville, United States +17 more
Started: Aug 10, 2016
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
NCT00783692COMPLETEDPHASE3
1.12K participants
INTERVENTIONAL
Birmingham, United States +113 more
Started: Dec 1, 2008
A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study
NCT02646683COMPLETEDPHASE4
260 participants
INTERVENTIONAL
Antwerp, Belgium +22 more
Started: Jul 1, 2015
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
NCT01224171COMPLETEDPHASE3
416 participants
INTERVENTIONAL
Lafayette, United States +40 more
Started: Nov 1, 2010
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
NCT02559713COMPLETEDPHASE4
11 participants
INTERVENTIONAL
Aurora, United States +6 more
Started: Nov 29, 2017
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
NCT00619489COMPLETEDPHASE2
72 participants
INTERVENTIONAL
London, Canada
Started: Dec 1, 2007
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT03196427COMPLETEDPHASE2
59 participants
INTERVENTIONAL
Los Angeles, United States +22 more
Started: Jul 30, 2018
Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT03138655COMPLETEDPHASE2
89 participants
INTERVENTIONAL
Los Angeles, United States +87 more
Started: Nov 8, 2017
Showing 20 of 97 total trials